1. Current dosage and schedule issues in the development of paclitaxel (Taxol®);Arbuck;Semin Oncol,1993
2. Arbuck SG, Christian MC, Fisherman JS, et al: The clinical development of paclitaxel (Taxol®). J Natl Cancer Inst Monograph. Proc Second NCI Workshop on Taxol and Taxus, in press
3. Arbuck SG, Strauss H, Rowinsky E, et al: A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Monograph. Proc Second NCI Workshop on Taxol and Taxus, in press
4. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia;Bodey;Ann Intern Med,1966
5. Boggs BA, Gonzalez-Garay ML, O’Brien WE, et al: Mechanisms of resistance to drugs that target microtubules (abstract). Proc Second Interface of Clinical and Laboratory Responses to Anticancer Drugs: Drugs and Microtubules Marseilles, April 2–4, 1992, p 13